1994 Volume 42 Issue Supplement4 Pages 314-321
We performed basic and clinical studies on biapenem (BIPM), a new carbapenem, and obtained following results. The in vitro antibacterial activity of BIPM against 360 clinical isolates from 14 species was compared with that of imipenem, panipenem, meropenem and cefpirome. BIPM showed more activity against gram-positive bacteria except Enterococus faecalis, and gram-negative bacteria than other carbapenems. In clinical studies, BIPM (0.6g per day) was given to 10 patients with respiratory infections, cystitis and cholecystitis for 7-15 days. Clinical response was excellent in 4 cases, good in 3, fair in 1 and poor in 2. Neither side effects nor abnormal laboratory findings were observed.
